<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02142634</url>
  </required_header>
  <id_info>
    <org_study_id>BUG-3/MIC</org_study_id>
    <secondary_id>2013-001912-31</secondary_id>
    <nct_id>NCT02142634</nct_id>
  </id_info>
  <brief_title>Budesonide for Induction of Remission in Incomplete Microscopic Colitis</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Multi-centre Trial on the Efficacy and Safety of Budesonide for Induction of Remission in Incomplete Microscopic Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of
      active incomplete microscopic colitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N.A.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical remission</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical remission</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical remission</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to remission</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of formed/soft/watery stools per week</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with abdominal pain</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with urgency</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of histological remission</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment at final visit</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Incomplete Microscopic Colitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide granules 9 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo granules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide granules 9 mg</intervention_name>
    <description>per day</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo granules</intervention_name>
    <description>per day</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically established diagnosis of incomplete microscopic colitis (MCi)

          -  History of chronic non-bloody, watery diarrhoea

          -  Clinically active disease

        Exclusion Criteria:

          -  Other significant abnormalities in colonoscopy

          -  Infectious cause of diarrhoea

          -  Clinical suspicion of drug-induced diarrhoea

          -  Prior and present MC

          -  History of bowel resection

          -  Radiation therapy of the abdominal or pelvic region

          -  Positive antibody titres for celiac disease

          -  Untreated active thyroid dysfunction

          -  Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder
             reducing life expectancy

          -  Abnormal hepatic function

          -  Tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease,
             glaucoma, cataract, or infection if careful medical monitoring is not ensured

          -  History of colorectal cancer

          -  History of cancer (other than colorectal) in the last 5 years

          -  Therapy with immunomodulators/budesonide or other steroids/antibiotics/anti-diarrhoeal
             drugs

          -  Current or intended pregnancy or breast-feeding

          -  Doubt about the patient's cooperation, e.g. because of addiction to alcohol or drugs

          -  Participation in another clinical trial within the last 30 days, simultaneous
             participation in another clinical trial, or previous participation in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Münch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Linköping, Dept. of Gastroenterology and Hepatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralf Mohrbacher, MSc</last_name>
    <phone>+49 761 1514</phone>
    <phone_ext>156</phone_ext>
    <email>mohrbacher@drfalkpharma.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roland Greinwald, PhD</last_name>
    <phone>+49 761 1514</phone>
    <phone_ext>0</phone_ext>
    <email>greinwald@drfalkpharma.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Digestive Diseases</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Miehlke, MD</last_name>
      <phone>+49 40 460</phone>
      <phone_ext>2001</phone_ext>
      <email>prof.miehlke@mdz-hamburg.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Miehlke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Linköping, Dept. of Gastroenterology and Hepatology</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Münch, MD</last_name>
      <phone>+46 101030000</phone>
      <email>andreas.munch@lio.se</email>
    </contact>
    <investigator>
      <last_name>Andreas Münch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Microscopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

